Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and a major cause of cancer mortality worldwide. At late stage of the disease CRC often shows (multiple) metastatic lesions in the peritoneal cavity which cannot be efficiently targeted by systemic chemotherapy. This is one major factor contributing to poor prognosis. Oxaliplatin is one of the most commonly used systemic treatment options for advanced CRC. However, drug resistance - often due to insufficient drug delivery - is still hampering successful treatment. The anticancer activity of oxaliplatin includes besides DNA damage also a strong immunogenic component. Consequently, the aim of this study was to investigate the effect of bacterial ghosts (BGs) as adjuvant immunostimulant on oxaliplatin efficacy. BGs are empty envelopes of gram-negative bacteria with a distinct immune-stimulatory potential. Indeed, we were able to show that the combination of BGs with oxaliplatin treatment had strong synergistic anticancer activity against the CT26 allograft, resulting in prolonged survival and even a complete remission in this murine model of CRC carcinomatosis. This synergistic effect was based on an enhanced induction of immunogenic cell death and activation of an efficient T-cell response leading to long-term anti-tumor memory effects. Taken together, co-application of BGs strengthens the immunogenic component of the oxaliplatin anticancer response and thus represents a promising natural immune-adjuvant to chemotherapy in advanced CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 1×
“In more detail, oxaliplatin-treated cancer cells were found to undergo immunogenic cell death (ICD), a particular form of cell death, which is characterized by distinct hallmarks, including calreticulin (CRT) exposure as well as release of ATP and high mobility group box 1 (HMGB1).(22) Furthermore, the high efficacy o…”
BackgroundImmunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
HMGB1 and RAGE in Inflammation and Cancer
Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R., & Coyle, A. J. (2010) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132603 · Cited by 1,436
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Development of a Syngeneic Mouse Model for Events Related to Ovarian Cancer
Roby, K. F., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G., & Terranova, P. F. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.585 · Cited by 593
Cited by
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Self-citationZhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152934 · Cited by 131
“, empty envelopes of Gram-negative bacteria) in OXA chemotherapy, and combined them with OXA to trigger antitumor T cell responses against CT26 murine colon cancer cells and establish long-term immune memory (Groza et al., 2018).”
BackgroundCan we harness the microbiota to enhance the efficacy of cancer immunotherapy?
Finlay, B. B., Goldszmid, R., Honda, K., Trinchieri, G., Wargo, J., & Zitvogel, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0374-6 · Cited by 81
Metadata
- Authors
- Groza, D., Gehrig, S., Kudela, P., Holcmann, M., Pirker, C., Dinhof, C., Schueffl, H. H., Sramko, M., Hoebart, J., Alioglu, F., Grusch, M., Ogris, M., Lubitz, W., Keppler, B. K., Pashkunova-Martic, I., Kowol, C. R., Sibilia, M., Berger, W., & Heffeter, P.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2018-02-16
- Volume
- 7
- Issue
- 5
- Pages
- e1424676-e1424676
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W2783688279
- Cited by
- 61
- References
- 6
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis. https://app.cochat.ai/papers/10.1080/2162402x.2018.1424676
- The paper
- Groza, D., Gehrig, S., Kudela, P., Holcmann, M., Pirker, C., Dinhof, C., Schueffl, H. H., Sramko, M., Hoebart, J., Alioglu, F., Grusch, M., Ogris, M., Lubitz, W., Keppler, B. K., Pashkunova-Martic, I., Kowol, C. R., Sibilia, M., Berger, W., & Heffeter, P. (2018). Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis. OncoImmunology. https://doi.org/10.1080/2162402x.2018.1424676
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.